By restoring macrophage efferocytosis, normalizing nitric oxide signaling, and dampening chronic inflammation, CD47 blockade has the potential to interrupt multiple convergent pathways driving AAA pathogenesis [18,20,40,41]. Here, CD47 is linked to triple-A syndrome.